Overview
Optain Health provides an AI-powered retinal imaging platform that screens for 140+ systemic and eye conditions. Its core product combines a portable fundus camera with AI-enabled Software as a Medical Device (SaMD) to analyze retinal images and generate a risk assessment in under a minute for clinicians. It is designed to fit into standard clinical workflows and serve providers, patients, and payers by standardizing care, enabling risk stratification, and reducing missed diagnoses. The goal is to enable early detection and preventive care at scale by making retinal AI screening fast, easy to deploy in clinical settings, and useful for guiding diagnoses and care decisions.
Work here?Claim your company
Simplify's take
What believers are saying
- Optain reported 250 global sites in May 2026, with 1,000 deployments planned.
- Insight Partners’ September 2025 Series A brought seven health systems and stronger distribution.
- Australia expansion with Bupa and Melbourne R&D adds funding, jobs, and APAC reach.
What critics are saying
- Zeiss launched Alta Duo 300 and PathFinder in November 2026, squeezing differentiation.
- Optain filed a 2026 SEC D offering still only half-sold, signaling cash burn.
- If health systems pause deployments, Optain loses its scaling story and acquisition rationale.
What makes Optain Health unique
- Optain combines AI retinal screening with EyePACS’ 740-site teleophthalmology network.
- Its robotic, point-of-care camera needs no dilation and fits primary-care workflows.
- Professor Mingguang He’s decade-long research gives Optain proprietary oculomics credibility.
Help us improve and share your feedback! Did you find this helpful?
Funding
Industry standards